NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

The “45–50 patients per month” figure some people keep quoting here is from an NWBO press release dated January 10, 2022. It described Phase 1A manual production in the B suites, before Flaskworks, before the Advent acquisition, before the C-lab redesign, and before the current MAA review cycle. It was a theoretical projection and was never achieved in practice.

That number does not represent 2025 capacity.
So when the new PR says the first Grade C suite will “more than double” the aggregate capacity of the existing B suites, you cannot simply plug in the old 2022 manual projections. We do not know the current real throughput of the B suites, and MHRA will not allow NWBO to publicly claim unvalidated capacity for an automated system before qualification and inspection.

“More than double” is a conservative, regulator-safe statement. Flaskworks almost certainly allows far more than a simple 2× increase, but NWBO cannot legally or strategically make bold capacity claims until MHRA has validated the automated C-suite workflow.